Esperion Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Esperion Therapeutics sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).
Esperion Therapeutics: 23 sponsored US clinical trials, 1 recruiting.
Esperion Therapeutics sponsors 23 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 22 completed. 8 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypercholesterolemia, with 4 trials.
Top-decile sponsor footprint
Esperion Therapeutics ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
23 total, page 1 of 1
Bempedoic Acid Pregnancy Surveillance Program
NCT05103254
Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
NCT06021951
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
NCT05694260
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
NCT03531905
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
NCT03337308
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
NCT03193047
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
NCT03067441
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
NCT03051100
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
NCT02993406
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
NCT03001076
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
NCT02991118
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
NCT02988115
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
NCT02666664
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
NCT02659397
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
NCT02178098
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
NCT02072161
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
NCT01941836
A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia
NCT01779453
A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance
NCT01751984
A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
NCT01607294
A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects
NCT01485146
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
NCT01262638
A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia
NCT01105598
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 12 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Esperion Therapeutics pipeline
1 recruiting of 23 indexed (4% open); 22 completed (96%).
Phase mix: 8 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Hypercholesterolemia (4 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Esperion Therapeutics: open-pipeline peers nationwide
Peers matched on 23 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Esperion Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 23 trials (± recruiting share)
- AMAG Pharmaceuticals · 23 trials · 9% recruiting
- AtriCure · 23 trials · 22% recruiting
- Cara Therapeutics · 23 trials · 0% recruiting
- Craig L Slingluff, Jr · 23 trials · 4% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Tonix Pharmaceuticals · 4% recruiting · 23 trials
- Rockefeller University · 4% recruiting · 117 trials
- Galderma R&D · 4% recruiting · 158 trials
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 4% recruiting · 45 trials
Related
What to do with this Esperion Therapeutics page
23 registered trials is a research-attention snapshot, not an endorsement of Esperion Therapeutics or any single study.
- 1 of Esperion Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hypercholesterolemia is the condition Esperion Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypercholesterolemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Esperion Therapeutics pipeline card: 23 registered trials from official public datasets.Report a data error.